NEW YORK, Sept. 28 (GenomeWeb News) - Celera Genomics and Genentech have signed a multi-year agreement to develop new cancer drugs based on targets derived from Celera's proteomics platform, Celera said today.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
